StemCell Institute
7096.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥2.8bn | ¥2.7bn | ¥2.5bn | ¥2.1bn | ¥1.8bn | ¥1.4bn |
| Operating income | ¥263m | ¥419m | ¥414m | ¥298m | ¥227m | ¥87m |
| Ordinary income | ¥278m | ¥429m | ¥417m | ¥300m | ¥213m | ¥92m |
| Total assets | ¥7.7bn | ¥7.5bn | ¥6.5bn | ¥5.8bn | ¥5.2bn | ¥4.0bn |
| Net assets / equity | ¥2.7bn | ¥2.6bn | ¥2.7bn | ¥2.3bn | ¥2.1bn | ¥1.3bn |
| Operating cash flow | — | ¥468m | ¥335m | ¥100m | ¥469m | ¥239m |
| EPS (basic) | ¥19.03 | ¥37.67 | ¥30.35 | ¥19.33 | ¥13.2r | ¥6.41r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 132 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 50 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 112 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 67 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 110 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 44 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 68 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 42 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 109 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 44 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 68 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 42 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 104 figures · EDINET |
4 more reports are still being processed.